Literature DB >> 3259048

Production of hepatitis B virus-infected human B-cell hybridomas: transmission of the viral genome to normal lymphocytes in cocultures.

G Colucci1, P Lyons, Y Beazer, S D Waksal.   

Abstract

The presence of hepatitis B virus (HBV) genome and transcripts in mononuclear cells from a patient with acute type B hepatitis offered the possibility of developing a cell line which could serve as a model for HBV replication in lymphocytes. A human B-cell hybridoma, KDG92, was then produced which carries HBV DNA in an episomal state and expresses the major virus transcripts as well as its surface (HBsAg), core (HBcAG), and e (HBeAg) antigens. KDG92 releases in the supernatant surface antigen particles but not core or Dane particles. However, in cocultures this hybridoma is able to transmit episomal HBV DNA to normal lymphocytes, both T and B cells. This in vitro system can therefore provide important indications as to the virus life cycle in lymphocytes and the mechanisms of virus propagation from cell to cell.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3259048     DOI: 10.1016/0042-6822(88)90641-1

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  3 in total

1.  Human immunodeficiency virus type 1 and hepatitis B virus transcription in peripheral blood lymphocytes from co-infected subjects.

Authors:  M Clementi; A Manzin; P Bagnarelli; S Menzo; P E Varaldo; G Carloni
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

2.  In vitro inhibition of hemopoietic cell line growth by hepatitis B virus.

Authors:  H S Steinberg; P Bouffard; C Trépo; J B Zeldis
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

3.  Repeated passage of wild-type woodchuck hepatitis virus in lymphoid cells does not generate cell type-specific variants or alter virus infectivity.

Authors:  Patricia M Mulrooney-Cousins; Tomasz I Michalak
Journal:  J Virol       Date:  2008-05-21       Impact factor: 5.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.